[40] Sallman DA,

DeZern AE, Steensma D, Sweet KL, Cluzeau T, Sekkeres M, et al. Phase 1b/2 combination study of APR-246 and azacitidine (AZA) in patients with *TP53* mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Blood 2018;132(Suppl 1):3091.

[41] Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia 2019; 33:905-17. doi: 10.1038/ s41375-018-0261-3.

[42] Kadia TM, Kantarjian HM, Konopleva M. Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy. Oncotarget 2019; 10:1250-65. DOI: 10.18632/oncotarget.26579

[43] Daver NG, Pollyea DA, Garcia JS, Jonas BA, Yee KWL, Fenaux P, et al. Safety, efficacy, pharmacokinetic (PK) and biomarker analyses of BCL2 inhibitor venetoclax (Ven) plus MDM2 inhibitor idasanutlin (idasa) in patients (pts) with relapsed or refractory (R/R) AML: a phase Ib, non-randomized, open-label study. Blood 2018;132(Suppl 1): 767.

[44] Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, Tang JL, et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.

Leukemia. 2011;25(2): 246-53. doi: 10.1038/leu.2010.267

[45] Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood. 2010;115(14):2749-54. doi: 10.1182/blood-2009-11-253070.

[46] Gaidzik VI, Paschka P, Spath D, Habdank M, Kohne CH, Germing U, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol. 2012; 30:1 350-1357. doi: 10.1200/ JCO.2011.39.2886.

[47] Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17:225-234. doi: 10.1016/j. ccr.2010.01.020.

[48] Stein EM, DiNardo D, Fathi AT, Pollyea DA, Stone RM, Altman JK, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019; 133:676-687. doi: 10.1182/blood-2018-08-869008.

[49] Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010; 116:2122-2126. doi: 10.1182/blood-2009-11-250878.

[50] Sharma H. Development of novel therapeutics targeting Isocitrate dehydrogenase mutations in Cancer. Curr Top Med Chem. 2018; 18:505-524. doi: 10.2174/1568026618666180518091 144.

**307**

*Mechanisms of Resistence of New Target Drugs in Acute Myeloid Leukemia*

acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130(6):732-741. doi: 10.1182/blood-2017-04-779447.

[59] Quek L, David MD, Kennedy A, Metzner M, Amatangelo MD, Shih A, Stoilova B, Quivoron C et al. Clonal heterogeneity of acute myeloid leukemia

[60] Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov. 2018;8(12): 1540-1547. doi: 10.1158/2159-8290.

[61] Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, et al. Acquired resistance to IDH inhibition through trans or cisdimer-interface mutations. Nature. 2018;559(7712):125-129. doi: 10.1038/

treated with the IDH2 inhibitor enasidenib. Nat Med. 2018;24(8):1167- 1177. doi: 10.1038/s41591-018-0115-6.

CD-18-0877.

s41586-018-0251-7

[62] Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T, Thiede C, Frattini M et al. Terminal myeloid differentiation in vivo is

induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012;120(20):4205-4214. doi: 10.1182/blood-2012-01-402545

[63] McMahon CM, Canaani J, Rea B, Sargent RL, Qualtieri JN, Watt CD, Morrissette JJD et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv. 2019;3(10):1581-1585. doi: 10.1182/bloodadvances.2018029496.

[64] Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, et al. Isocitrate dehydrogenase

1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 2015;21: 178-84. DOI: 10.1038/

nm.3788.

*DOI: http://dx.doi.org/10.5772/intechopen.94978*

[51] Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18: 553-67. doi: 10.1016/j.

[52] Bertoli S, Tavitian S, Delabesse E, Sarry A, Huguet F, Recher C. Outcome of AML patients with IDH1 or IDH2 mutations from diagnosis and refractory/ relapse phase of the disease in routine practice. Blood. 2016;128(22):1718.

[53] Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011;118(2):409-412. doi: 10.1182/

[54] Kim ES. Enasidenib: First Global Approval. Drugs. 2017;77(15):1705-11. doi: 10.1007/s40265-017-0813-2

[55] Dhillon S. Ivosidenib: First Global Approval. Drugs. 2018;78(14):1509-16. doi: 10.1007/s40265-018-0978-3.

[56] Choe S, Wang H, DiNardo CD, Stein EM, de Botton S, Roboz GJ et al. Molecular mechanisms mediating relapse following ivosidenib

monotherapy in *IDH1*-mutant relapsed or refractory AML. Blood Adv. 2020; 4: 1894-1905.Blood Adv. 2020 May 12;4(9):1894-1905. doi: 10.1182/ bloodadvances.2020001503

[57] DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords

Shih A, Stein EM, Roshal M, David MD, Marteyn B et al. Enasidenib induces

R et al. Durable remissions with ivosidenib in *IDH1*-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386-2398. doi: 10.1056/

[58] Amatangelo MD, Quek L,

NEJMoa1716984.

blood-2010-12-322479.

ccr.2010.11.015.

*Mechanisms of Resistence of New Target Drugs in Acute Myeloid Leukemia DOI: http://dx.doi.org/10.5772/intechopen.94978*

[51] Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18: 553-67. doi: 10.1016/j. ccr.2010.11.015.

*Acute Leukemias*

JCO.2011.40.7783.

[39] Lambert JM, Gorzov P,

10.1016/j.ccr.2009.03.003.

[40] Sallman DA,

refractory hematologic malignancies and prostate cancer. J. Clin. Oncol. 2012; 30: 3633-3639. DOI: 10.1200/

Leukemia. 2011;25(2): 246-53. doi:

[45] Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood. 2010;115(14):2749-54. doi: 10.1182/blood-2009-11-253070.

[46] Gaidzik VI, Paschka P, Spath D, Habdank M, Kohne CH, Germing U, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol. 2012; 30:1 350-1357. doi: 10.1200/

[47] Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD,

Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17:225-234. doi: 10.1016/j.

[48] Stein EM, DiNardo D, Fathi AT, Pollyea DA, Stone RM, Altman JK, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019; 133:676-687. doi: 10.1182/blood-2018-08-869008.

[49] Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010; 116:2122-2126. doi: 10.1182/blood-2009-11-250878.

[50] Sharma H. Development of novel therapeutics targeting Isocitrate dehydrogenase mutations in Cancer. Curr Top Med Chem. 2018; 18:505-524. doi: 10.2174/1568026618666180518091

10.1038/leu.2010.267

JCO.2011.39.2886.

ccr.2010.01.020.

144.

Veprintsev DB, Söderqvist M, Segerbäck D et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009; 15:376-388. DOI:

DeZern AE, Steensma D, Sweet KL, Cluzeau T, Sekkeres M, et al. Phase 1b/2 combination study of APR-246 and azacitidine (AZA) in patients with *TP53* mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Blood 2018;132(Suppl 1):3091.

[41] Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia

2019; 33:905-17. doi: 10.1038/

[42] Kadia TM, Kantarjian HM,

10.18632/oncotarget.26579

Konopleva M. Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy. Oncotarget 2019; 10:1250-65. DOI:

[43] Daver NG, Pollyea DA, Garcia JS, Jonas BA, Yee KWL, Fenaux P, et al. Safety, efficacy, pharmacokinetic (PK) and biomarker analyses of BCL2 inhibitor venetoclax (Ven) plus MDM2 inhibitor idasanutlin (idasa) in patients (pts) with relapsed or refractory (R/R) AML: a phase Ib, non-randomized, open-label study. Blood 2018;132(Suppl

[44] Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, Tang JL, et al. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.

s41375-018-0261-3.

**306**

1): 767.

[52] Bertoli S, Tavitian S, Delabesse E, Sarry A, Huguet F, Recher C. Outcome of AML patients with IDH1 or IDH2 mutations from diagnosis and refractory/ relapse phase of the disease in routine practice. Blood. 2016;128(22):1718.

[53] Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011;118(2):409-412. doi: 10.1182/ blood-2010-12-322479.

[54] Kim ES. Enasidenib: First Global Approval. Drugs. 2017;77(15):1705-11. doi: 10.1007/s40265-017-0813-2

[55] Dhillon S. Ivosidenib: First Global Approval. Drugs. 2018;78(14):1509-16. doi: 10.1007/s40265-018-0978-3.

[56] Choe S, Wang H, DiNardo CD, Stein EM, de Botton S, Roboz GJ et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in *IDH1*-mutant relapsed or refractory AML. Blood Adv. 2020; 4: 1894-1905.Blood Adv. 2020 May 12;4(9):1894-1905. doi: 10.1182/ bloodadvances.2020001503

[57] DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R et al. Durable remissions with ivosidenib in *IDH1*-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386-2398. doi: 10.1056/ NEJMoa1716984.

[58] Amatangelo MD, Quek L, Shih A, Stein EM, Roshal M, David MD, Marteyn B et al. Enasidenib induces

acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130(6):732-741. doi: 10.1182/blood-2017-04-779447.

[59] Quek L, David MD, Kennedy A, Metzner M, Amatangelo MD, Shih A, Stoilova B, Quivoron C et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. 2018;24(8):1167- 1177. doi: 10.1038/s41591-018-0115-6.

[60] Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov. 2018;8(12): 1540-1547. doi: 10.1158/2159-8290. CD-18-0877.

[61] Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, et al. Acquired resistance to IDH inhibition through trans or cisdimer-interface mutations. Nature. 2018;559(7712):125-129. doi: 10.1038/ s41586-018-0251-7

[62] Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T, Thiede C, Frattini M et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012;120(20):4205-4214. doi: 10.1182/blood-2012-01-402545

[63] McMahon CM, Canaani J, Rea B, Sargent RL, Qualtieri JN, Watt CD, Morrissette JJD et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv. 2019;3(10):1581-1585. doi: 10.1182/bloodadvances.2018029496.

[64] Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 2015;21: 178-84. DOI: 10.1038/ nm.3788.

[65] Dinardo C, Takahashi K, Kadia T, Loghavi S, Naqvi K, Bose P, et al. A phase 1b/2 clinical study of targeted IDH1 inhibition with ivosidenib, in combination with the BCL-2 inhibitor venetoclax, for patients with IDH1-mutated (MIDH1) myeloid malignancies. HemaSphere 2019; 3:97.

[66] Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res 2014; 20:490-8. doi: 10.1158/1078-0432. CCR-13-1311.

[67] Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, et al. Oral MEK 1/2 inhibitor trametinib in combination with AKT inhibitor GSK2141795 in patients with acute myeloid leukemia with RAS mutations: a phase II study. Clin Lymphoma Myeloma Leuk 2019;19: 431-40. doi: 10.1016/j.clml.2019.03.015.

[68] Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 2019;125: 1470-81. doi: 10.1002/cncr.31896.

[69] Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117:4501-10. doi: 10.1182/ blood-2010-10-310425.

[70] Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res 2014; 2:4. doi: 10.1186/2050-7771-2-4.

[71] Uy GL, Rettig MP, Vey N, Godwin J, Foster MC, Rizzieri D, et al. Phase 1 cohort expansion of flotetuzumab, a CD123-CD3 bispecific Dart® protein in patients with relapsed/refractory acute myeloid leukemia (AML). Blood 2018;132(Suppl 1):764.

[72] Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, et al. A CD123-targeting antibodydrug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv 2018; 2:848-58. doi: 10.1182/ bloodadvances.2018017517.

[73] Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, openlabel, phase II study. Cancer Discov 2019; 9: 370-83. doi: 10.1158/2159-8290. CD-18-0774.

[74] Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138:286-99. DOI: 10.1016/j.cell.2009.05.045.

[75] Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012; 109: 6662-7. doi: 10.1073/pnas.1121623109.

[76] Pietsch EC, Dong J, Cardoso R, Zhang X, Chin D, Hawkins R, et al. Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. Blood Cancer J 2017;7: e536. doi: 10.1038/bcj.2017.7.

[77] Sallman D, Donnellan W, Asch A, Lee D, Al Malki M, Pollyea D, et al.

**309**

*Mechanisms of Resistence of New Target Drugs in Acute Myeloid Leukemia*

*DOI: http://dx.doi.org/10.5772/intechopen.94978*

The first-in-class anti-CD47 antibody HU5F9-G4 is active and well tolerated alone or in combination with azacitidine in AML and MDS patients: initial phase 1b results: S878. HemaSphere 2019; 3:

[78] Fan M, Li M, Gao L, Geng S, Wang J, Wang Y, et al. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia. J Hematol Oncol 2017; 10: 151. doi: 10.1186/

[79] Short NJ, Ravandi F. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? Haematologica 2019; 104:1532-41. doi: 10.3324/

s13045-017-0519-7.

haematol.2018.208454.

394.

*Mechanisms of Resistence of New Target Drugs in Acute Myeloid Leukemia DOI: http://dx.doi.org/10.5772/intechopen.94978*

The first-in-class anti-CD47 antibody HU5F9-G4 is active and well tolerated alone or in combination with azacitidine in AML and MDS patients: initial phase 1b results: S878. HemaSphere 2019; 3: 394.

*Acute Leukemias*

CCR-13-1311.

[65] Dinardo C, Takahashi K, Kadia T, Loghavi S, Naqvi K, Bose P, et al. A phase 1b/2 clinical study of targeted IDH1 inhibition with ivosidenib, in combination with the BCL-2 inhibitor venetoclax, for patients with IDH1-mutated (MIDH1) myeloid malignancies. HemaSphere 2019; 3:97.

[71] Uy GL, Rettig MP, Vey N, Godwin J, Foster MC, Rizzieri D, et al. Phase 1 cohort expansion of flotetuzumab, a CD123-CD3 bispecific Dart® protein in patients with relapsed/refractory acute myeloid leukemia (AML). Blood

2018;132(Suppl 1):764.

CD-18-0774.

[72] Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, et al. A CD123-targeting antibodydrug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv 2018; 2:848-58. doi: 10.1182/ bloodadvances.2018017517.

[73] Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, openlabel, phase II study. Cancer Discov 2019; 9: 370-83. doi: 10.1158/2159-8290.

[74] Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138:286-99. DOI:

[75] Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012; 109: 6662-7. doi:

10.1016/j.cell.2009.05.045.

10.1073/pnas.1121623109.

doi: 10.1038/bcj.2017.7.

[76] Pietsch EC, Dong J, Cardoso R, Zhang X, Chin D, Hawkins R, et al. Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. Blood Cancer J 2017;7: e536.

[77] Sallman D, Donnellan W, Asch A, Lee D, Al Malki M, Pollyea D, et al.

[66] Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous

leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res 2014; 20:490-8. doi: 10.1158/1078-0432.

[67] Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, et al. Oral MEK 1/2 inhibitor trametinib in combination with AKT inhibitor GSK2141795 in patients with acute myeloid leukemia with RAS mutations: a phase II study. Clin Lymphoma Myeloma Leuk 2019;19: 431-40. doi:

[68] Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 2019;125: 1470-81. doi: 10.1002/cncr.31896.

[69] Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117:4501-10. doi: 10.1182/

[70] Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res 2014; 2:4.

10.1016/j.clml.2019.03.015.

blood-2010-10-310425.

doi: 10.1186/2050-7771-2-4.

**308**

[78] Fan M, Li M, Gao L, Geng S, Wang J, Wang Y, et al. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia. J Hematol Oncol 2017; 10: 151. doi: 10.1186/ s13045-017-0519-7.

[79] Short NJ, Ravandi F. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? Haematologica 2019; 104:1532-41. doi: 10.3324/ haematol.2018.208454.
